Skip to main navigation
logo

Investor Navigation

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials
    • SEC Filings
  • Governance
    • Documents & Charters
    • Board of Directors
    • Executive Team
    • Committee Composition
  • IR Resources
    • Investor FAQ
    • Contact IR
    • Email Alerts

Press Releases

10 May '2023
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
03 Apr '2023
Context Therapeutics to Participate in Two April 2023 Investor Conferences
22 Mar '2023
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
15 Mar '2023
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
06 Feb '2023
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
31 Jan '2023
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
09 Jan '2023
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
04 Jan '2023
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Investor Tools

  • Print Page
  • RSS Feeds
  • Search

© 2023 Context Therapeutics Inc.     All rights reserved.